Jpmorgan Chase & CO Immunic, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Immunic, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 407 shares of IMUX stock, worth $468. This represents 0.0% of its overall portfolio holdings.
Number of Shares
407
Previous 407
-0.0%
Holding current value
$468
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding IMUX
# of Institutions
68Shares Held
57.6MCall Options Held
600Put Options Held
254K-
Avidity Partners Management LP Dallas, TX8.9MShares$10.2 Million0.45% of portfolio
-
Bvf Inc San Francisco, CA8.9MShares$10.2 Million0.35% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$8.39 Million0.79% of portfolio
-
Janus Henderson Group PLC London, X06.99MShares$8.04 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$6.43 Million0.01% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $35.1M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...